Home » Stocks » AGRX

Agile Therapeutics, Inc. (AGRX)

Stock Price: $2.81 USD -0.03 (-1.06%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $2.84 +0.03 (1.07%) Jan 15, 7:57 PM
Market Cap 245.69M
Revenue (ttm) n/a
Net Income (ttm) -40.25M
Shares Out 87.35M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $2.81
Previous Close $2.84
Change ($) -0.03
Change (%) -1.06%
Day's Open 2.82
Day's Range 2.81 - 2.86
Day's Volume 714,058
52-Week Range 1.58 - 4.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will ...

GlobeNewsWire - 3 weeks ago

PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morga...

Seeking Alpha - 1 month ago

Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA ...

GlobeNewsWire - 1 month ago

Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)

GlobeNewsWire - 1 month ago

PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, r...

GlobeNewsWire - 1 month ago

PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer...

The Motley Fool - 2 months ago

The drugmaker will soon give Twirla a twirl.

Seeking Alpha - 2 months ago

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Commercial Launch of Twirla® Expected by Year-End 2020

GlobeNewsWire - 2 months ago

Live Conference Call and Webcast at 4:30 p.m. ET

GlobeNewsWire - 3 months ago

PRINCETON, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually...

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that Al Altomari, Chairman and Chi...

GlobeNewsWire - 4 months ago

Company to Present Twirla® Commercial Plan

GlobeNewsWire - 4 months ago

Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options

GlobeNewsWire - 4 months ago

PRINCETON, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD,...

Seeking Alpha - 5 months ago

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Offic...

GlobeNewsWire - 5 months ago

Live Conference Call and Webcast at 4:30 p.m. ET

Zacks Investment Research - 6 months ago

Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 6 months ago

PRINCETON, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® ...

Seeking Alpha - 8 months ago

Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.

The Motley Fool - 8 months ago

Agile's shares are heating up ahead of the company's Q1 earnings report.

Seeking Alpha - 8 months ago

Agile Therapeutics: Billion Dollar Buy-Out Is On The Horizon

GlobeNewsWire - 8 months ago

PRINCETON, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sha...

Zacks Investment Research - 9 months ago

Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.

Zacks Investment Research - 9 months ago

Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.

The Motley Fool - 10 months ago

The biotech stock is getting hit hard by the marketwide downturn today. Here's why.

The Motley Fool - 10 months ago

Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.

The Motley Fool - 10 months ago

Shares drop after the company releases the pricing details of a recently announced capital raise.

Zacks Investment Research - 10 months ago

Agile Therapeutics (AGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 10 months ago

Is (AGRX) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 10 months ago

PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 1...

GlobeNewsWire - 10 months ago

PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its comm...

The Motley Fool - 10 months ago

Twirla now has a green light from the FDA. And that could mean a green light for investors looking for a promising small-cap biotech stock.

24/7 Wall Street - 10 months ago

Agile Therapeutics Inc. (NASDAQ: AGRX) shares took a dip on Tuesday after the company announced a key U.S.

Seeking Alpha - 10 months ago

Agile Could Reach $10/Share After Twirla Approval

Other stocks mentioned: MDCO
Seeking Alpha - 10 months ago

Coronavirus is having a major impact across sectors.

GlobeNewsWire - 11 months ago

Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S.

The Motley Fool - 11 months ago

The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.

The Motley Fool - 11 months ago

Bargain-seeking investors might want to look at these three stocks before venturing into the risky world of penny stocks.

Other stocks mentioned: SAN
GlobeNewsWire - 11 months ago

Funding to Support the Company’s Commercialization Plans for Twirla ®

Seeking Alpha - 11 months ago

Short-Term Catalyst And Long-Term M&A Potential Make Agile Therapeutics An Attractive Potential Takeover Target

The Motley Fool - 11 months ago

From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.

Other stocks mentioned: ABBV, AMRN, ESPR, LLY, MRK
Seeking Alpha - 11 months ago

Agile Therapeutics' Market Potential, And Other News: The Good, Bad, And Ugly Of Biopharma

Seeking Alpha - 11 months ago

Agile: Recent AdCom Decisions Further Support Twirla Approval

Seeking Alpha - 11 months ago

Agile Therapeutics: 400%+ Upside

Zacks Investment Research - 1 year ago

Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.

Other stocks mentioned: AIRI, DERM, MBOT, SAVA
GlobeNewsWire - 1 year ago

PRINCETON, N.J., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Kimberly Whelan as Vice President...

Seeking Alpha - 1 year ago

Agile: FDA Decision To Extend Twirla's PDUFA Date Provides Buying Opportunity

About AGRX

Agile Therapeutics, a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG2... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
May 23, 2014
CEO
Alfred Altomari
Employees
15
Stock Exchange
NASDAQ
Ticker Symbol
AGRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is 8.25, which is an increase of 193.59% from the latest price.

Price Target
$8.25
(193.59% upside)
Analyst Consensus: Buy